Published in J Clin Invest on April 01, 2003
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest (2007) 9.09
The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int (2008) 3.30
Genetic factors of age-related macular degeneration. Prog Retin Eye Res (2004) 2.17
International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol Rev (2013) 2.11
CX3CR1-dependent renal macrophage survival promotes Candida control and host survival. J Clin Invest (2013) 2.00
Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the brachiocephalic artery, not the aortic root. Proc Natl Acad Sci U S A (2004) 2.00
Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity (2009) 1.95
A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension (2009) 1.94
Macrophage heterogeneity and tissue lipids. J Clin Invest (2007) 1.89
Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.76
Fractalkine and CX 3 CR1 regulate hippocampal neurogenesis in adult and aged rats. Neurobiol Aging (2009) 1.72
Immunopathological aspects of age-related macular degeneration. Semin Immunopathol (2008) 1.63
Impact of aging vs. estrogen loss on cardiac gene expression: estrogen replacement and inflammation. Physiol Genomics (2011) 1.56
Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes (2011) 1.44
Therapeutic targeting of chemokine interactions in atherosclerosis. Nat Rev Drug Discov (2010) 1.38
Detection of CX3CR1 single nucleotide polymorphism and expression on archived eyes with age-related macular degeneration. Histol Histopathol (2005) 1.32
CCL2/CCR2 and CX3CL1/CX3CR1 chemokine axes and their possible involvement in age-related macular degeneration. J Neuroinflammation (2010) 1.18
Reduced microglial CX3CR1 expression delays neurofibromatosis-1 glioma formation. Ann Neurol (2013) 1.14
The fate of monocytes in atherosclerosis. J Thromb Haemost (2009) 1.09
Chemokines and chemokine receptors in arthritis. Front Biosci (Schol Ed) (2010) 1.06
The role of microglia in diabetic retinopathy. J Ophthalmol (2014) 1.00
Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Pathol (2004) 1.00
The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. J Clin Invest (2003) 0.98
Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction. Blood (2007) 0.97
Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci (2016) 0.97
Regulation of adaptive immunity by the fractalkine receptor during autoimmune inflammation. J Immunol (2013) 0.95
Fractalkine is expressed in early and advanced atherosclerotic lesions and supports monocyte recruitment via CX3CR1. PLoS One (2012) 0.93
Respiratory syncytial virus G protein CX3C motif impairs human airway epithelial and immune cell responses. J Virol (2013) 0.92
Neuron-Microglia Dialogue and Hippocampal Neurogenesis in the Aged Brain. Aging Dis (2010) 0.92
An oxidized lipid-peroxisome proliferator-activated receptor gamma-chemokine pathway in the regulation of macrophage-vascular smooth muscle cell adhesion. Trends Cardiovasc Med (2007) 0.89
Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J Mol Endocrinol (2009) 0.87
Decreased Th17 and antigen-specific humoral responses in CX₃ CR1-deficient mice in the collagen-induced arthritis model. Arthritis Rheum (2012) 0.87
Role of fractalkine/CX3CL1 and its receptor in the pathogenesis of inflammatory and malignant diseases with emphasis on B cell malignancies. Mediators Inflamm (2014) 0.87
Functional adhesiveness of the CX3CL1 chemokine requires its aggregation. Role of the transmembrane domain. J Biol Chem (2008) 0.86
Fractalkine promotes human monocyte survival via a reduction in oxidative stress. Arterioscler Thromb Vasc Biol (2014) 0.85
Roles of the chemokine system in development of obesity, insulin resistance, and cardiovascular disease. J Immunol Res (2014) 0.85
Constitutive endocytosis of the chemokine CX3CL1 prevents its degradation by cell surface metalloproteases. J Biol Chem (2009) 0.85
Chemokines and angiogenesis in rheumatoid arthritis. Front Biosci (Elite Ed) (2009) 0.84
Analysis of Hemicentin-1, hOgg1, and E-selectin single nucleotide polymorphisms in age-related macular degeneration. Trans Am Ophthalmol Soc (2005) 0.83
Greater fractalkine expression in mesenteric arteries of female spontaneously hypertensive rats compared with males. Am J Physiol Heart Circ Physiol (2009) 0.82
CX3CR1 is dispensable for control of mucosal Candida albicans infections in mice and humans. Infect Immun (2014) 0.82
Search for an association between V249I and T280M CX3CR1 genetic polymorphisms, endothelial injury and preeclampsia: the ECLAXIR study. PLoS One (2009) 0.82
Phagocytosis inhibits F-actin-enriched membrane protrusions stimulated by fractalkine (CX3CL1) and colony-stimulating factor 1. Infect Immun (2009) 0.82
Combinations of Polymorphic Markers of Chemokine Genes, Their Receptors and Acute Phase Protein Genes As Potential Predictors of Coronary Heart Diseases. Acta Naturae (2016) 0.82
Disruption of Fractalkine Signaling Leads to Microglial Activation and Neuronal Damage in the Diabetic Retina. ASN Neuro (2015) 0.81
Two polymorphisms in the Fractalkine receptor CX3CR1 gene influence the development of atherosclerosis: a meta-analysis. Dis Markers (2014) 0.81
Chemokine receptors CXCR2 and CX3CR1 differentially regulate functional responses of bone-marrow endothelial progenitors during atherosclerotic plaque regression. Cardiovasc Res (2015) 0.80
Expression and regulation of corticotropin-releasing factor receptor type 2β in developing and mature mouse skeletal muscle. Mol Endocrinol (2010) 0.80
Regulation of atherogenesis by chemokines and chemokine receptors. Arch Immunol Ther Exp (Warsz) (2012) 0.80
The impact of chemokine receptor CX3CR1 deficiency during respiratory infections with Mycobacterium tuberculosis or Francisella tularensis. Clin Exp Immunol (2009) 0.79
CX3CR1 deficiency delays acute skeletal muscle injury repair by impairing macrophage functions. FASEB J (2015) 0.78
Polymorphisms in chemokine and chemokine receptor genes and the development of coal workers' pneumoconiosis. Cytokine (2006) 0.78
Fractalkine receptor polymorphism and chronic tonsillitis. Eur Arch Otorhinolaryngol (2014) 0.77
Polymorphisms of Fractalkine receptor CX3CR1 and plasma levels of its ligand CX3CL1 in colorectal cancer patients. Int J Colorectal Dis (2007) 0.77
CX3CR1 is a modifying gene of survival and progression in amyotrophic lateral sclerosis. PLoS One (2014) 0.76
Common and Rare Genetic Variation in CCR2, CCR5, or CX3CR1 and Risk of Atherosclerotic Coronary Heart Disease and Glucometabolic Traits. Circ Cardiovasc Genet (2016) 0.76
The CXCR2 Gene Polymorphism Is Associated with Stroke in Patients with Essential Hypertension. Cerebrovasc Dis Extra (2015) 0.75
Circulating chemokine ligand levels before and after successful kidney transplantation. J Inflamm (Lond) (2016) 0.75
Relationship of Genetic Polymorphisms of the Chemokine, CCL5, and Its Receptor, CCR5, with Coronary Artery Disease in Taiwan. Evid Based Complement Alternat Med (2015) 0.75
TLR4-dependent internalization of CX3CR1 aggravates sepsis-induced immunoparalysis. Am J Transl Res (2016) 0.75
Effects on serum fractalkine by diet and omega-3 fatty acid intervention: relation to clinical outcome. Mediators Inflamm (2015) 0.75
Association of chemokine receptor CX3CR1 V249I and T280M polymorphisms with chronic kidney disease. Indian J Nephrol (2016) 0.75
Genetic background of psoriasis. Int J Health Sci (Qassim) (2010) 0.75
Genetic variants in platelet factor 4 modulate inflammatory and platelet activation biomarkers. Circ Cardiovasc Genet (2012) 0.75
Fractalkine Signaling Attenuates Perivascular Clustering of Microglia and Fibrinogen Leakage during Systemic Inflammation in Mouse Models of Diabetic Retinopathy. Front Cell Neurosci (2017) 0.75
Fractalkine receptor polymorphism may not be associated with the development and clinical course of ulcerative colitis. Bosn J Basic Med Sci (2015) 0.75
Downregulation of CX3CR1 ameliorates experimental colitis: evidence for CX3CL1-CX3CR1-mediated immune cell recruitment. Int J Colorectal Dis (2016) 0.75
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
Inflammation and atherosclerosis. Circulation (2002) 20.77
An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol (1979) 18.84
Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol (2000) 14.74
Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature (1998) 8.92
A new class of membrane-bound chemokine with a CX3C motif. Nature (1997) 7.87
Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell (1998) 7.46
International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 7.17
The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol (1994) 6.82
Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell (1997) 6.70
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med (1998) 4.16
Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med (2002) 3.96
Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature (1997) 3.74
Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation (2003) 3.55
Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest (2003) 3.19
Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem (2001) 2.91
Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood (2001) 2.87
6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3beta receptor CCR7. J Cell Biol (1998) 2.62
Genetic polymorphism in CX3CR1 and risk of HIV disease. Science (2000) 2.38
A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest (1998) 2.37
Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis (1999) 2.35
Association between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosis. Circ Res (2001) 2.33
Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem (1999) 2.24
Chemokines and atherosclerosis. Atherosclerosis (1999) 2.14
Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J (1990) 1.87
The Framingham study. An epidemiological approach to coronary heart disease. Circulation (1966) 1.72
Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1 -2518 G/G genotype in CAD patients. Atherosclerosis (2001) 1.72
Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science (2000) 1.70
Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem (1998) 1.64
Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol (2002) 1.62
The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res (2000) 1.60
Tumor necrosis factor-alpha-converting enzyme mediates the inducible cleavage of fractalkine. J Biol Chem (2001) 1.58
CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol (2000) 1.53
A role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejection. J Immunol (2000) 1.49
Characterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular disease. Cardiovasc Pathol (2002) 1.41
Surveillance for morbidity and mortality among older adults--United States, 1995-1996. MMWR CDC Surveill Summ (1999) 1.40
Fractalkine-mediated endothelial cell injury by NK cells. J Immunol (2000) 1.34
Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest (2001) 1.31
Epidemiology and risk profile of cardiac failure. Cardiovasc Drugs Ther (1988) 1.29
Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int (1999) 1.25
Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur J Neurosci (2002) 1.24
Genetic variation at the chemokine receptors CCR5/CCR2 in myocardial infarction. Genes Immun (2001) 1.17
Linked chromosome 16q13 chemokines, macrophage-derived chemokine, fractalkine, and thymus- and activation-regulated chemokine, are expressed in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (2001) 1.15
Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol (1999) 1.10
Val64Ile polymorphism in the C-C chemokine receptor 2 is associated with reduced coronary artery calcification. Arterioscler Thromb Vasc Biol (2002) 1.04
Mutational analysis of the fractalkine chemokine domain. Basic amino acid residues differentially contribute to CX3CR1 binding, signaling, and cell adhesion. J Biol Chem (2001) 0.96
Metabolic risk factors for coronary heart disease: current and future prospects. Curr Opin Cardiol (1999) 0.85
Chemokines and their receptors in infectious disease. Springer Semin Immunopathol (2000) 0.82
Weighing the evidence for infection as a risk factor for coronary heart disease. Curr Cardiol Rep (2000) 0.80
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet (2008) 20.66
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation (2006) 19.43
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics (2008) 15.77
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation (2011) 14.00
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Metabolite profiles and the risk of developing diabetes. Nat Med (2011) 12.22
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet (2009) 12.19
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med (2004) 11.46
Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med (2002) 11.20
Variants in MTNR1B influence fasting glucose levels. Nat Genet (2008) 10.85
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation (2013) 10.24
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol (2007) 9.90
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet (2007) 9.80
Genotype score in addition to common risk factors for prediction of type 2 diabetes. N Engl J Med (2008) 9.68
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 8.90
Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation (2004) 8.80
Incidence of diabetes in youth in the United States. JAMA (2007) 8.70
Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study. Arch Intern Med (2007) 8.59
Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation (2005) 8.54
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts. Circ Cardiovasc Genet (2009) 8.42
Application of new cholesterol guidelines to a population-based sample. N Engl J Med (2014) 8.22
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94
Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol (2003) 7.47
Predictors of new-onset kidney disease in a community-based population. JAMA (2004) 7.45
Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet (2009) 7.27
The burden of diabetes mellitus among US youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics (2006) 7.19
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA (2007) 6.95
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med (2002) 6.92
Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA (2002) 6.84
Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation (2003) 6.83
Obesity and the risk of new-onset atrial fibrillation. JAMA (2004) 6.73
Disclosure of APOE genotype for risk of Alzheimer's disease. N Engl J Med (2009) 6.43
Presentation of multivariate data for clinical use: The Framingham Study risk score functions. Stat Med (2004) 6.42
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet (2006) 6.39
Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation (2007) 6.34
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med (2007) 6.29
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation (2006) 5.97
Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation (2008) 5.95
Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med (2011) 5.94
Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet (2008) 5.89
A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. BMC Med Genet (2007) 5.64
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
New loci associated with kidney function and chronic kidney disease. Nat Genet (2010) 5.58
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. JAMA (2004) 5.34
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab (2006) 5.33
Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet (2009) 5.32
Genomewide association studies of stroke. N Engl J Med (2009) 5.29